A Phase III Randomized Trial Of Chemotherapy With Or Without Bevacizumab In Patients With Recurrent Or Metastatic Head And Neck Cancer
Posted Date: May 15, 2019
- Investigator: John Morris
- Type of Study: Drug
This study will compare the good and bad effects of the addition of bevacizumab to the standard chemotherapy to see which works better. This combination is experimental. Bevacizumab is approved by the FDA for colorectal cancer not for head and neck cancer. This study will last several months and fol
Criteria:
Eligible Patients Must Have Been Diagnosed With Recurrent Or Metastatic Head And Neck Cancer
Keywords:
E1305, Head And Neck Cancer, Metastatic , Recurrent
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu